Význam nových biomarkerů při hodnocení pokročilosti srdečního selhání

Abstract

5 Abstract Chronic heart failure (CHF) is a serious medical problem, the incidence and prevalence of which are constantly increasing in developed countries. The disease has a poor prognosis, and diagnosis and treatment are challenging, not only medically but also economically. Although the prognosis of patients with CHF has improved significantly due to advances in the treatment of heart failure in recent decades, reduced quality of life and still high mortality persist. The use of established mortality risk factors such as the determination of the degree of functional impairment using the NYHA (New York Heart Association) classification, the need for specific treatment, some laboratory values, and the assessment of cardiac function with the determination of left ventricular ejection fraction (LVEF) do not accurately predict the risk of death of an individual patient with heart failure. Laboratory determination of specific biological indicators of various pathophysiological processes - biomarkers - can contribute to the specification of this risk. These are various biological substances that are identified as parameters of cardiac overload, myocardial dysfunction, remodeling, fibrosis, cardiomyocyte damage, etc. and that appear in increased concentrations in the blood of patients with this syndrome. The...

3 Abstrakt prevalence v jen medicínsky, ale i ekonomicky. v mortalita. stanovení míry klasifikace NYHA (New York Heart Assotiation), nutnost - koncentraci v krvi nemocných s tímto syndromem. -natriuretický peptid (BNP) a N-terminální fragment prohormonu B- natriuretického peptidu (NT- diagnostice v s v BNP nebo NT- v 4 s vztah k -proBNP jsou GDF-15 (Growth differentiation factor 15 15) a cystatin C slibnými biomarkery ke stanovení - (solubilní receptor ST2 - Supression of tumorgenicity 2) jako markeru myokardiální fibrózy a IMP-1 matrixové metaloproteinázy-1 - Tissue inhibitors of metalloproteinases-1) jsou spojeny s (LK). emodelace: NT-proBNP a k procesu vaskulární remodelace: apelinu a ADMA (asymetrický dimethylarginin).